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Abstract: The analyses of the retrospective database of the 
International Association for the Study of Lung Cancer (IASLC), 
consisting of more than 81,000 evaluable patients diagnosed with 
lung cancer between 1990 and 2000, formed the basis of recom-
mendations to the Union for International Cancer Control and the 
American Joint Committee on Cancer for the revision of the sixth 
edition of the tumor, node, and metastasis (TNM) classification of 
lung cancer. However, despite the large number of patients, not all 
descriptors could be validated. This prompted a new collection of 
retrospective and prospective data to overcome the limitations of the 
original retrospective database. The new IASLC database has infor-
mation on 94,708 new patients diagnosed of lung cancer between 
1999 and 2010. They originated from 35 sources in 16 countries, and 
4,667 were submitted via the online electronic data capture system. 
Europe contributed 46,560 patients, Asia: 41,705, North America: 
4,660, Australia: 1,593, and South America: 190. After exclusions, 
77,156 (70,967 with nonsmall cell lung cancer and 6,189 with small 
cell lung cancer) remained for analysis. This database will be ana-
lyzed according to established objectives for the T, the N, and the M 
components to inform the eighth edition of the TNM classification 
of lung cancer due to be published in 2016. The IASLC hopes for the 
continuing contribution of our partners around the world to improve 
the classification of anatomical extent of disease, but also to create 
prognostic groups in a parallel project of the IASLC Staging and 
Prognostic Factors Committee.
Key Words: Lung cancer, Lung cancer databases, Lung cancer 
staging, Nonsmall cell lung cancer, Small cell lung cancer, TNM 
classification.
(J Thorac Oncol. 2014;9: 1618–1624)
The call for action launched during the International Workshop on Intrathoracic Staging, that took place in 
London, United Kingdom, in October 19961 to revise and 
improve the tumor, node, and metastasis (TNM) classification 
of lung cancer, resulted in an unprecedented response from 
groups and institutions around the world. By 2005, data on 
100,869 patients diagnosed of lung cancer between 1990 and 
2000 were submitted to the International Association for the 
Study of Lung Cancer (IASLC) database at Cancer Research 
And Biostatistics (CRAB). These data originated from 46 
different sources in 20 countries of Europe, North America, 
Asia, and Australia. After exclusions, 81,495 patients were 
available for analyses: 68,463 with nonsmall cell lung cancer 
(NSCLC) and 13,032 with small cell lung cancer (SCLC).2 
From the analyses of these data, a series of research articles 
on the T,3 the N,4 and the M5 components of the TNM clas-
sification were peer-reviewed and published in the Journal of 
Thoracic Oncology for public discussion. In a similar manner, 
a revised stage grouping was proposed,6 the new findings were 
internally and externally validated,7 and the TNM classifica-
tion was tested and validated for SCLC8,9 and, for the first time 
in the history of the anatomical staging of malignant tumors, 
for broncho-pulmonary carcinoids.10 In addition, a new lymph 
node map, resulting from an international and multidisci-
plinary consensus and reconciling the differences of the pre-
vious ones, was proposed for prospective validation;11 and a 
new definition of visceral pleura invasion was agreed based on 
the published data.12 The nonanatomic information included 
in the database was used to create prognostic groups before 
and after surgical treatment based on the combination of ana-
tomic staging and very simple clinical variables, such as age, 
gender, and performance status.13,14 The recommendations for 
changes in the TNM classification of lung cancer derived from 
the analyses of the IASLC database (Table 1) were submitted 
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to the Union for International Cancer Control (UICC) and 
the American Joint Committee on Cancer (AJCC), and were 
accepted and subsequently published in the seventh edition of 
their staging manuals.15,16 At the same time, the IASLC pro-
duced the Staging Handbook in Thoracic Oncology and the 
Staging Manual in Thoracic Oncology including the TNM 
classifications of lung cancer and mesothelioma, the general 
rules of the TNM classification, site-specific rules for lung 
cancer and mesothelioma, and complementary chapters on 
survival analyses, prognostic factors, frequently asked ques-
tions and the history of the TNM classification since its incep-
tion by Pierre Denoix in the mid 20th century.17,18 With this 
contribution, the IASLC became the primary source of data-
based evidence to revise subsequent editions of the UICC and 
the AJCC TNM classifications of thoracic malignancies.
Despite the vastness of the IASLC database, not all 
descriptors of the T, the N, and the M components of the ana-
tomical classification could be validated. The main reason was 
that many of the original datasets of the contributing databases 
had not been designed to study the TNM classification. The 
resulting lack of detailed data prevented the analyses of many 
descriptors. For the T component, only could tumor size, addi-
tional tumor nodule(s) and pleural effusion be analyzed reli-
ably. For the N component, the present categories could be 
validated in the clinical and pathological staging. However, the 
TABLE 1.  Innovations Introduced in the seventh Edition 
of the Tumor, Node, and Metastases Classification of Lung 
Cancer
Descriptor/TNM
Category/Stage in  
the sixth Edition
Category/Stage in 
the seventh Edition
Tumor size ≤ 2 cm T1 T1a
Tumor size > 2 cm  
but ≤ 3 cm
T1 T1b
Tumor size > 3 cm  
but ≤ 5 cm
T2 T2a
Tumor size > 5 cm  
but ≤ 7 cm
T2 T2b
Tumor size > 7 cm T2 T3
Additional tumor nodule(s)  
in the same lobe of the  
primary tumor
T4 T3
Additional tumor nodule(s)  
in another ipsilateral lobe
M1 T4
Pleural dissemination 
(malignant pleural  
effusion and separated 
pleural nodules)
T4 M1a
Pericardial dissemination  
(malignant pericardial 
effusion  
and separated pericardial 
nodules)
N/A M1a
Intrathoracic metastases M1 M1a
Extrathoracic metastases M1 M1b
T2b N0 M0 IB IIA
T2a N1 M0 IIB IIA
T4 N0-1 M0 IIIB IIIA
TABLE 2.  Number of Cases Submitted by Each Data Source, 
by Continent
Region Data Source EDC Source N
Asia EDC Guangdong General Hospital, China 739
Shanghai Lung Tumor Clinical 
Medical Center, China
51
Japan 1999 13,344
Japan 2002 14,695
Japan 2004 10,889
South Korea 1,987
Australia EDC Peter MacCallum Cancer Centre 4
Prince 
Charles
229
Sydney 1,360
Europe Belgrade, 
Serbia
88
Denmark 33,949
EDC Athens School of Medicine, Greece 39
Clinical Center of Serbia, Serbia 40
GCCB-S, Spain 2,362
L’Institut Mutualiste  
Montsouris, France
120
Military Medical Academy, Serbia 20
Antwerp University Hospital, 
Multidisciplinary Oncological 
Centre Antwerp (MOCA), Belgium
195
University Hospital Ghent, Belgium 85
University of Torino, Italy 4
Norway 2,354
Turkey 7,304
North and  
South  
America
EDC Alexander Fleming Institute, Argentina 6
Clinica y Maternidad Suizo Argentina, 
Argentina
3
Fundación Clínica  
Valle del Lili, Colombia
2
Good Samaritan Hospital, USA 10
Hospital Británico de Buenos Aires, 
Argentina
68
Hospital Universitario Austral, 
Argentina
46
Hospital Universitario-Fundación 
Favaloro, Argentina
36
Hospital de Rehabilitación 
Respiratoria, Argentina
14
Mayo Clinic Rochester, USA 47
New York University Langone Medical 
Center and Cancer Center, USA
688
Penrose Cancer Center, USA 73
University of Sao Paulo Medical 
School, Brazil
15
MDACC, 
USA
2,415
MSKCC, 
USA
1,427
Global Total 94,708
GCCB-S, Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española 
de Neumología y Cirugía Torácica; NYU, New York University; MDACC, M. D. 
Anderson Cancer Center; MSKCC, Memorial Sloan-Kettering Cancer Center.
1620 Copyright © 2014 by the International Association for the Study of Lung Cancer
Rami-Porta et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014
new information on the prognostic impact of nodal tumor bur-
den represented by the number of involved nodal zones found 
at pathological staging could not be used to modify the N cat-
egories because it could not be validated at clinical staging, by 
geographical regions or by the different T categories. Finally, 
in the M component, although there was enough information 
to separate intrathoracic from extrathoracic metastases, noth-
ing could be said about the prognostic impact of number and 
site of metastases.19 These limitations prompted the IASLC 
Staging and Prognostic Factors Committee to launch a second 
phase of its Lung Cancer Staging Project with the objective to 
overcome the limitations of the initial project,20 and to restruc-
ture its membership (Appendix 2).
THE NEW IASLC DATABASE
The new database, the analyses of which will inform 
the eighth edition of the TNM classification of lung cancer, 
consists of 94,708 patients diagnosed from 1999 to 2010. 
Their data originated from established databases (90,041 
patients) or were submitted via the electronic data capture 
(EDC) system set by Cancer Research And Biostatistics 
(4,667 patients). The EDC allows the contributors to submit 
data online and retrieve their own data for their own stud-
ies at any time. Europe contributed 46,560 patients, Asia: 
41,705, North America: 4,660, Australia: 1,593, and South 
America: 190. These new data came from 35 sources in 16 
countries (Table 2). After excluding 17,552 patients, mainly 
because of unknown or different histology and incomplete 
stage information, 77,156 patients (70,967 with NSCLC 
and 6,189 with SCLC) remained for analyses (Table 3). The 
majority of these patients (99%) had been collected by con-
sortia or registries. There were no patients from clinical tri-
als (Table 4). Nearly 85% of the patients underwent surgical 
treatment either alone or in combination with chemotherapy 
or radiotherapy (Table 5). This is reflected in the stage dis-
tribution of NSCLC: except in Europe, where there is pre-
dominance of advanced stages, early stages are predominant, 
especially in Asia; for SCLC, advanced stages are predomi-
nant, as expected (Figure 1).
This new database is being analyzed according to con-
crete objectives for each of the T, the N, and the M compo-
nents of the classification. In essence, the principal aims are to 
further explore and analyze the impact on prognosis of tumor 
size and of the different T descriptors; the prognostic signifi-
cance of tumor burden in hilar and mediastinal lymph nodes; 
and the confirmation of the revised M1 categories (M1a and 
M1b) of the seventh edition of the classification along with 
the prognostic impact of number and anatomic location of 
metastases.20 For this phase of the study, in addition to the 
data elements collected in the initial phase,2 the descriptors 
TABLE 3.  Number of Cases Submitted to the Database, 
With Exclusions and the Numbers Remaining for Analysis
Submitted 94,708
Excluded 17,552
  Carcinoids 745
  Other or unknown histology 5,986
  Outside 1999–2010 timeframe 525
  Incomplete survival data 938
  Incomplete stage information 9,286
  Multiple synchronous tumors 72
Included in initial analyses 77,156
  NSCLC 70,967
  SCLC 6,189
TABLE 4.  Number of Cases Analyzed by Type of Data 
Source
Other EDC Total
Data source type
  Consortium 41,548 2,089 43,637
  Registry 26,122 26,122
  Surgical series 5,373 592 5,965
  Institutional series 1,185 1,185
  Institutional registry 208 208
  Unknown 39 39
Total 73,251 3,905 77,156
Consortium: group of institutions where all individuals diagnosed with lung cancer 
are registered. Registry: all individuals diagnosed with lung cancer in a defined region, 
including those diagnosed at death. Surgical series: all individuals diagnosed with 
lung cancer and treated by a particular surgeon or unit. Institutional series: same as 
consortium, but in a single institution; may be limited to a specific treatment specialty 
or specialties. Institutional registry: all individuals diagnosed with lung cancer and 
admitted to a particular institution are registered.
TABLE 5.  Comparison of Basic Elements of the Two IASLC 
Databases Used for Informing the seventh Edition and the 
eighth Edition of the TNM Classification of Lung Cancer
Element Database for the 
seventh Edition
Database for the  
eighth Edition
Period of diagnosis 1990 to 2000 1999 to 2010
Total patients submitted 100,869 94,708
Geographical origin
  Europe 58,701 (58%) 46,560 (49%)
  North America 21,130 (21%) 4,660 (5%)
  Asia 11,622 (11.5%) 41,705 (44%)
  Australia 9,416 (9.3%) 1,593 (1.7%)
  South America 0 190 (0.3%)
Patients excluded 19,374 (19%) 17,552 (18%)
Patients included for 
analyses
81,495 77,154
  NSCLC 68,463 (84%) 70,967 (92%)
  SCLC 13,032 (16%) 6,189 (8%)
Treatment modalities
  Surgery alone 41% 57.7%
  Radiotherapy + surgery 5% 1.5%
  Chemotherapy + surgery 4% 21.1%
  Chemotherapy alone 23% 9.3%
  Radiotherapy alone 11% 1.5%
  Chemotherapy + 
radiotherapy
12% 4.7%
  Trimodality 3% 4.4%
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of the TNM classification were collected according to its 
seventh edition. Moreover, 23 nonanatomical elements were 
included in the data dictionary to prepare for the development 
of prognostic groups (Table 6). The combination of anatomic 
and nonanatomic elements in a combined prognostic index 
enhances the capacity to prognosticate beyond that of the 
TNM classification alone. These combined prognostic indexes 
will help personalize prognosis for a given patient.
The new database is almost as large as the one used for 
the seventh edition. As a matter of fact, some of the already 
established databases that have been submitted were not spe-
cifically designed to study the TNM classification and have the 
same limitations as the original IASLC database. However, 
the data contributed via the EDC contained all the necessary 
elements to do so. Although smaller in number of patients, it 
is much richer in details to allow refinements in the analyses 
of the different descriptors. Europe still is the leading contrib-
uting region, closely followed by Asia, thanks to the massive 
participation of Japan. In relation to the previous database, the 
cases from North America and Australia have dropped; and 
South America is represented by a few cases for the first time. 
Patients undergoing surgical treatment alone are predominant, 
as in the previous database. Owing to the nature of the data 
sources (no clinical trials), the number of patients treated with 
chemotherapy alone or in combination with radiotherapy has 
dropped. This database contains a similar number of patients 
with NSCLC, but the number of patients with SCLC has been 
reduced by 50% (Table 5).
FIGURE 1.  Histograms of stage (pathological stage, if 
provided; otherwise, clinical stage) distribution by region. (A) 
Nonsmall cell lung cancer; (B) small cell lung cancer; and (C) 
overall.
TABLE 6.  Nonanatomical Elements Collected in the New 
Phase of the IASLC Lung Cancer Staging Project
Patient-related 
elements
Age
Sex
Race
Smoking history
Weight loss
Zubrod performance status
Comorbidity index
Laboratory analyses: LDH, hemoglobin, calcium, 
alkaline phosphatase, sodium, leukocyte count, 
neutrophil count, platelets, albumin
Lung function tests: FVC and % of predicted; 
FEV1 and % of predicted
Weight
Height
Tumor-related 
elements
SUVmax for T and for N
Lobar, bronchial location of primary tumor
Differentiation grade
Histological type
Vascular invasion
Lymphatic invasion
Pleural lavage cytology
Tumor markers in those centers that have  
the possibility to determine them
Environment-related 
elements
Method of detection: symptoms,  
screening, incidental
Treatment
Residual tumor after treatment
Geographic area: continent, country of origin
LDH: lactate-dehydrogenase; FVC: forced vital capacity; FEV1: forced expiratory 
volume in 1 second; SUVmax: maximum standardized uptake value; T: primary tumor; 
N: lymph nodes
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The analyses of the new database and the findings sug-
gesting recommendations for the revision of the seventh edi-
tion of the TNM classification of lung cancer will be submitted 
to the Journal of Thoracic Oncology to make them available 
to the worldwide oncology community. The suggested recom-
mendations and their supportive data will also be submitted 
to the UICC and the AJCC for their assessment and inclusion 
in their new staging manuals, due to be published in 2016. 
The new edition of the classification will then be enacted in 
January 2017.
The contributing institutions are to be thanked for their 
touching generosity and enthusiasm. This is an ongoing proj-
ect that will soon be complemented by a deeper study on 
prognostic factors, for which prospective data collection will 
be essential. We hope that this new project will be appeal-
ing to the international lung cancer community and will be 
supported again by our regular contributors and, hopefully, by 
new ones. Although there are several ways to contribute,21 the 
best way to serve the objectives of the IASLC Lung Cancer 
Staging Project is to submit cases via the EDC. The online 
dataset contains the specific data elements needed to study the 
descriptors of the three components of the TNM classifica-
tion and to refine prognosis. Your collaboration will be much 
welcome.
APPENDIX 1. IASLC Staging and Prognostic 
Factors Committee
Peter Goldstraw, Past Chair, Royal Brompton Hospital 
and Imperial College, London, United Kingdom; Ramón 
Rami-Porta, Chair, Hospital Universitari Mutua Terrassa, 
Terrassa, Spain; Hisao Asamura, Chair Elect, National Cancer 
Center, Tokyo, Japan; David Ball, Peter MacCallum Cancer 
Centre, Melbourne, Australia; David Beer, University of 
Michigan, Ann Arbor, MI, USA; Ricardo Beyruti, University 
of Sao Paulo, Brazil; Vanessa Bolejack, Cancer Research 
And Biostatistics, Seattle, WA, USA; Kari Chansky, Cancer 
Research And Biostatistics, Seattle, WA, USA; John Crowley, 
Cancer Research And Biostatistics, Seattle, WA, USA; 
Frank Detterbeck, Yale University, New Haven, CT, USA; 
Wilfried Ernst Erich Eberhardt, West German Cancer Centre, 
University Hospital, Ruhrlandklinik, University Duisburg-
Essen, Essen, Germany; John Edwards, Northern General 
Hospital, Sheffield, United Kingdom; Françoise Galateau-
Sallé, Centre Hospitalier Universitaire, Caen, France; Dorothy 
Giroux, Cancer Research And Biostatistics, Seattle, WA, 
USA; Fergus Gleeson, Churchill Hospital, Oxford, United 
Kingdom; Patti Groome, Queen’s Cancer Research Institute, 
Kingston, Ontario, Canada; James Huang, Memorial Sloan-
Kettering Cancer Center, New York, NY, USA; Catherine 
Kennedy, University of Sydney, Sydney, Australia; Jhingook 
Kim, Samsung Medical Center, Seoul, Korea; Young Tae 
Kim, Seoul National University, Seoul, South Korea; Laura 
Kingsbury, Cancer Research And Biostatistics, Seattle, WA, 
USA; Haruhiko Kondo, Kyorin University Hospital, Tokyo, 
Japan; Mark Krasnik, Gentofte Hospital, Copenhagen, 
Denmark; Kaoru Kubota, Nippon Medical School Hospital, 
Tokyo, Japan; Antoon Lerut, University Hospitals, Leuven, 
Belgium; Gustavo Lyons, British Hospital, Buenos Aires, 
Argentina; Mirella Marino, Regina Elena National Cancer 
Institute, Rome, Italy; Edith M. Marom, MD Anderson Cancer 
Center, Houston, TX, USA; Jan van Meerbeeck, Antwerp 
University Hospital, Edegem (Antwerp), Belgium; Alan 
Mitchell, Cancer Research And Biostatistics, Seattle, WA, 
USA; Takashi Nakano, Hyogo College of Medicine, Hyogo, 
Japan; Andrew G. Nicholson, Royal Brompton and Harefield 
NHS Foundation Trust and Imperial College, London, United 
Kingdom; Anna Nowak, University of Western Australia, 
Perth, Australia; Michael Peake, Glenfield Hospital, Leicester, 
United Kingdom; Thomas Rice, Cleveland Clinic, Cleveland, 
OH, USA; Kenneth Rosenzweig, Mount Sinai Hospital, New 
York, NY, USA; Enrico Ruffini, University of Torino, Torino, 
Italy; Valerie Rusch, Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA; Nagahiro Saijo, National 
Cancer Center Hospital East, Chiba, Japan; Paul Van Schil, 
Antwerp University Hospital, Edegem (Antwerp), Belgium; 
Jean-Paul Sculier, Institut Jules Bordet, Brussels, Belgium; 
Lynn Shemanski, Cancer Research And Biostatistics, Seattle, 
WA, USA; Kelly Stratton, Cancer Research And Biostatistics, 
Seattle, WA, USA; Kenji Suzuki, Juntendo University, Tokyo, 
Japan; Yuji Tachimori, National Cancer Center, Tokyo, Japan; 
Charles F. Thomas Jr, Mayo Clinic, Rochester, MN, USA; 
William Travis, Memorial Sloan-Kettering Cancer Center, 
New York, NY, USA; Ming S. Tsao, The Princess Margaret 
Cancer Centre, Toronto, Ontario, Canada; Andrew Turrisi, 
Sinai Grace Hospital, Detroit, MI, USA; Johan Vansteenkiste, 
University Hospitals, Leuven, Belgium; Hirokazu Watanabe, 
National Cancer Center Hospital, Tokyo, Japan; Yi-Long Wu, 
Guangdong Provincial Peoples Hospital, Guangzhou, People’s 
Republic of China.
Advisory Board of the IASLC Mesothelioma Domain
Paul Baas, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands; Jeremy Erasmus, MD Anderson 
Cancer Center, Houston, TX, USA; Seiki Hasegawa, Hyogo 
College of Medicine, Hyogo, Japan; Kouki Inai, Hiroshima 
University Postgraduate School, Hiroshima, Japan; Kemp 
Kernstine, City of Hope, Duarte, CA, USA; Hedy Kindler, The 
University of Chicago Medical Center, Chicago, IL, USA; Lee 
Krug, Memorial Sloan-Kettering Cancer Center, New York, 
NY, USA; Kristiaan Nackaerts, University Hospitals, Leuven, 
Belgium; Harvey Pass, New York University, NY, USA; David 
Rice, MD Anderson Cancer Center, Houston, TX, USA.
Advisory Board of the IASLC Thymic Malignancies 
Domain
Conrad Falkson, Queen’s University, Ontario, Canada; 
Pier Luigi Filosso, University of Torino, Italy; Giuseppe 
Giaccone, Georgetown University, Washington, DC, USA; 
Kazuya Kondo, University of Tokushima, Tokushima, Japan; 
Marco Lucchi, University of Pisa, Pisa, Italy; Meinoshin 
Okumura, Osaka University, Osaka, Japan.
Advisory Board of the IASLC Esophageal Cancer 
Domain
Eugene Blackstone, Cleveland Clinic, OH, USA.
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Participating Institutions in the new IASLC Lung 
Cancer Staging Project
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MacCallum Cancer Centre, Melbourne, Australia; G. K. 
Bascom, Good Samaritan Hospital, Kearney, NE, USA; A. I. 
Blanco Orozco and M. A. González Castro, Hospital Virgen 
del Rocío, Sevilla, Spain; M. G. Blum, Penrose Cancer 
Center, Colorado Springs, USA; D. Chimondeguy, Hospital 
Universitario Austral, Argentina; V. Cvijanovic, Military 
Medical Academy, Belgrade, Serbia; S. Defranchi, Hospital 
Universitario-Fundación Favaloro, Buenos Aires, Argentina; 
B. de Olaiz Navarro, Hospital de Getafe, Getafe, Spain; I. 
Escobar Campuzano and I. Macía Vidueira, Hospital de 
Bellvitge, L’Hospitalet de Llobregat, Spain; E. Fernández 
Araujo and F. Andreo García, Hospital Universitari Germans 
Trias i Pujol, Badalona, Spain; K. M. Fong, Prince Charles 
Hospital, Brisbane, Australia; G. Francisco Corral and S. 
Cerezo González, Hospital La Mancha Centro, Ciudad Real, 
Spain; J. Freixinet Gilart, Hospital Universitario “Dr. Negrín,” 
Las Palmas de Gran Canaria, Spain; L. García Arangüena, 
Hospital Sierrallana, Torrelavega, Spain; S. García Barajas, 
Hospital Infanta Cristina, Badajoz, Spain; P. Girard, L’Institut 
Mutualiste Montsouris, Paris, France; T. Goksel, Turkish 
Thoracic Society, Turkey; M. T. González Budiño, Hospital 
General Universitario de Oviedo, Oviedo, Spain; G. González 
Casaurrán, Hospital Gregorio Marañón, Madrid, Spain; J. 
A. Gullón Blanco, Hospital San Agustín, Avilés, Spain; J. 
Hernández Hernández, Hospital de Ávila, Avila, Spain; H. 
Hernández Rodríguez, Hospital Universitario de Tenerife, 
Santa Cruz de Tenerife, Spain; J. Herrero Collantes, Hospital 
Universitario Nuestra Señora de la Candelaria, Santa Cruz de 
Tenerife, Spain; M. Iglesias Heras, Hospital de Ávila, Ávila, 
Spain; J. M. Izquierdo Elena, Hospital Nuestra Señora de 
Aránzazu, Donostia, Spain; E. Jakobsen, Danish Lung Cancer 
Registry, Denmark; S. Kostas, Athens School of Medicine, 
Athens, Greece; P. León Atance and A. Núñez Ares, Complejo 
Hospitalario de Albacete, Albacete, Spain; M. Liao, Shanghai 
Lung Tumor Clinical Medical Center, Shanghai, China; 
M. Losanovscky, Clinica y Maternidad Suizo Argentina, 
Buenos Aires, Argentina; G. Lyons, Hospital Británico de 
Buenos Aires, Buenos Aires, Argentina; R. Magaroles and 
L. De Esteban Júlvez, Hospital Joan XXIII, Tarragona, 
Spain; M. Mariñán Gorospe, Hospital de San Pedro de 
Logroño, Logroño, Spain; B. McCaughan and C. Kennedy, 
University of Sydney, Sydney, Australia; R. Melchor Íñiguez, 
Fundación Jiménez Díaz, Madrid, Spain; L. Miravet Sorribes, 
Hospital La Plana, Castellón, Spain; S. Naranjo Gozalo and 
C. Álvarez de Arriba, Hospital Universitario Marqués de 
Valdecilla, Santander, Spain; M. Núñez Delgado, Hospital de 
Meixoeiro, Vigo, Spain; J. Padilla Alarcón and J. C. Peñalver 
Cuesta, Instituto Valenciano de Oncología, Valencia, Spain; 
J. S. Park, Samsung Medical Center, Seoul, South Korea; 
H. Pass, New York University Langone Medical Center and 
Cancer Center, New York, USA; M. J. Pavón Fernández, 
Hospital “Severo Ochoa,” Leganés, Spain; M. Rosenberg, 
Alexander Fleming Institute and Hospital de Rehabilitación 
Respiratoria, Buenos Aires, Argentina; E. Ruffini, University 
of Torino, Torino, Italy; V. Rusch, Memorial Sloan-Kettering 
Cancer Center, New York, USA; J. Sánchez de Cos Escuín, 
Hospital de Cáceres, Cáceres, Spain; A. Saura Vinuesa, 
Hospital de Sagunto, Sagunto, Spain; M. Serra Mitjans, 
Hospital Universitari Mutua Terrassa, Terrassa, Spain; T. E. 
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